NCT04385719View on ClinicalTrials.gov

Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

July 2, 2021

Study Completion Date

July 16, 2021

Conditions
EbolaHIV/AIDS
Interventions
DRUG

Remdesivir

Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses

Trial Locations (1)

Unknown

Infectious Diseases Institute, Kampala

All Listed Sponsors
collaborator

University of Liverpool

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

University of Turin, Italy

OTHER

lead

Makerere University

OTHER